logo-loader
viewOpen Orphan PLC

Open Orphan joins coronavirus battle

Its subsidiary hVIVO owns Europe's only quarantine clinic with an onsite virology lab where the challenge model will be developed and used

Open Orphan PLC -

Open Orphan PLC’s (LON:ORPH) hVIVO virology and vaccine operation has begun the world’s first human coronavirus challenge study.

Also known as a controlled human infection model, at its simplest, it is a method of testing potential vaccines against certain illnesses in a locked-down medical facility.

hVIVO owns Europe's only quarantine clinic with an onsite virology lab where the challenge model will be developed and used.

Volunteers will be exposed to common coronavirus strains such as OC43 and 229E.

While from the same family of viruses as the newly emerging Covid-19 virus, they are different in so much as they have been widespread in the community for many years. As such, they cause only a mild cold-like respiratory illness.

Open Orphan said these common coronavirus strains mentioned above can safely be administered to volunteers in a highly controlled quarantine clinic where to date 3,000 people have been safely inoculated against a range of respiratory virus challenge models.

Open Orphan said it was in early discussions with King & Wood Mallesons, acting for “selected Chinese pharmaceutical and life science clients”, to secure funding for the expansion of its coronavirus efforts.

Chairman Cathal Friel said the study was an “important milestone in the development and evolution of Open Orphan” and its hVIVO subsidiary.

“We are very happy to be able to try and assist in the battle against Covid-19,” he added.

“Our hVIVO scientists and virologists, and especially hVIVO's founder and the now chairman of our scientific advisory board, Professor John Oxford, have a long history and experience of successfully developing challenge studies.

“This development also reinforces the strength of hVIVO's reputation as a world leader in providing services to global vaccine and anti-viral production companies and is another example of the growth potential for Open Orphan.”

Last Friday (March 6), the company inked a deal with an unnamed European biotech worth at least £7mln to carry out a human challenge study for respiratory syncytial virus, the cause of mild colds.

Quick facts: Open Orphan PLC

Price: 13.2001 GBX

AIM:ORPH
Market: AIM
Market Cap: £87.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan: New deal with top-three pharma company is 'evidence validation...

Proactive Research analyst Emma Ulker says the news this morning that Open Orphan PLC (LON:ORPH) subsidiary hVIVO has signed a £4mln contract with an unnamed top-three global pharma company is evidence that the validation is building as well as recognition amongst larger players in the industry....

4 days, 3 hours ago

2 min read